Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CING | US
0.33
7.19%
Healthcare
Biotechnology
30/06/2024
21/10/2024
4.92
4.65
4.94
4.55
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.6%1 month
62.5%3 months
640.6%6 months
478.3%-
-
4.53
0.11
0.06
-0.36
-
-
-18.05M
14.98M
14.98M
-
-
-
-
-1.36K
0.05
0.95
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.84
Range1M
1.12
Range3M
20.62
Rel. volume
0.94
Price X volume
550.14K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.244 | 15.97M | 0.16% | n/a | 118.63% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.36 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 4.53 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 640.57 | 72.80 | Riskier |
Debt to Equity | 0.11 | -1.23 | Expensive |
Debt to Assets | 0.06 | 0.25 | Cheaper |
Market Cap | 14.98M | 3.66B | Emerging |